About Organigram Global Inc.
https://www.organigram.caOrganigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada.
CEO
Peter L. Amirault
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public May 21, 2019
Method of going public IPO
Full time employees 1,093
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-07 | Reverse | 1:4 |
| 2015-01-28 | Reverse | 1:67 |
ETFs Holding This Stock
Summary
Total 6
Showing Top 3 of 6
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
ETF MANAGERS GROUP, LLC
Shares:7.35M
Value:$11.84M
TOROSO INVESTMENTS, LLC
Shares:2.34M
Value:$3.77M
MORGAN STANLEY
Shares:1.18M
Value:$1.9M
Summary
% Of Shares Owned 11.82%
Total Number Of Holders 86
Showing Top 3 of 86
Market Cap $232.62 M
52w High $2.24
52w Low $0.85
P/E -11.5
Volume 1.14M
Outstanding Shares 134.46M
About Organigram Global Inc.
https://www.organigram.caOrganigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $6.97M ▼ | $-9.14M ▼ | $-37.96M ▼ | -544.57% ▼ | $-0.2 ▼ | $-11.28M ▼ |
| Q3-2025 | $70.79M ▲ | $28.25M ▲ | $-6.29M ▼ | -8.89% ▼ | $-0.05 ▼ | $2.68M ▲ |
| Q2-2025 | $65.6M ▲ | $26M ▲ | $42.46M ▲ | 64.72% ▲ | $0.33 ▲ | $-2.74M ▲ |
| Q1-2025 | $42.73M ▼ | $25.12M ▲ | $-22.96M ▼ | -53.73% ▼ | $-0.2 ▼ | $-3.41M ▼ |
| Q4-2024 | $44.7M | $16.93M | $-5.43M | -12.15% | $-0.05 | $7.27M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $60.61M ▲ | $403.67M ▼ | $152.99M ▼ | $250.68M ▼ |
| Q3-2025 | $36.78M ▲ | $564.62M ▲ | $179.12M ▲ | $385.5M ▼ |
| Q2-2025 | $14.05M ▼ | $537.9M ▲ | $147.34M ▼ | $390.57M ▲ |
| Q1-2025 | $46.8M ▼ | $479.21M ▲ | $155.56M ▲ | $323.65M ▲ |
| Q4-2024 | $107.57M | $407.86M | $101.87M | $305.99M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-37.96M ▼ | $-946.32K ▼ | $57.44K ▲ | $-405.67K ▲ | $-2.43M ▼ | $-397.77K ▼ |
| Q3-2025 | $-6.29M ▼ | $14.63M ▲ | $-9.43M ▲ | $-560K ▼ | $2.53M ▼ | $5M ▲ |
| Q2-2025 | $42.46M ▲ | $-16.59M ▼ | $-10.3M ▲ | $40.66M ▲ | $13.82M ▲ | $-23.14M ▼ |
| Q1-2025 | $-22.96M ▼ | $-4.18M ▼ | $-61.55M ▼ | $-202K ▼ | $-63.92M ▼ | $-5.82M ▼ |
| Q4-2024 | $-5.43M | $8.89M | $-22.41M | $41.01M | $27.49M | $7M |
CEO
Peter L. Amirault
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public May 21, 2019
Method of going public IPO
Full time employees 1,093
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-07 | Reverse | 1:4 |
| 2015-01-28 | Reverse | 1:67 |
ETFs Holding This Stock
Summary
Total 6
Showing Top 3 of 6
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
ETF MANAGERS GROUP, LLC
Shares:7.35M
Value:$11.84M
TOROSO INVESTMENTS, LLC
Shares:2.34M
Value:$3.77M
MORGAN STANLEY
Shares:1.18M
Value:$1.9M
Summary
% Of Shares Owned 11.82%
Total Number Of Holders 86
Showing Top 3 of 86